Rankings
▼
Calendar
EBS Q1 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$446M
Q1 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$164M
-46.6% YoY
Gross Profit
-$24M
-14.8% margin
Operating Income
-$148M
-89.8% margin
Net Income
-$186M
-113.3% margin
EPS (Diluted)
$-3.65
QoQ Revenue Growth
-50.2%
Cash Flow
Operating Cash Flow
-$184M
Free Cash Flow
-$199M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$2.9B
Total Liabilities
$1.7B
Stockholders' Equity
$1.2B
Cash & Equivalents
$430M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$164M
$308M
-46.6%
Gross Profit
-$24M
$106M
-123.0%
Operating Income
-$148M
$6M
-2406.3%
Net Income
-$186M
-$4M
-4932.4%
Revenue Segments
Product
$143M
87%
Contract Development And Manufacturing
$15M
9%
Contracts and Grants
$7M
4%
Geographic Segments
Services Segment
$15M
100%
← FY 2023
All Quarters
Q2 2023 →